A common feature of Th2-mediated skin diseases is selective eosinophil (Eo) infiltration in the affected dermis. However, the mechanisms of selective Eo recruitment are not yet fully understood. Our recent findings indicated that dermal fibroblasts actively participate in the accumulation of Eo in Th2-mediated skin inflammation. Following stimulation with IL-4, dermal fibroblasts produce eotaxin, which is the only biologically active Eo attractant detected in the supernatants. Natural eotaxin is comprised of a mixture of N-terminal-truncated and O-glycosylated variants. The expression of eotaxin mRNA is upregulated within 1 h after stimulation. TNF-α markedly enhances eotaxin mRNA expression and release of the protein product from IL-4-stimulated fibroblasts. As mast cells and Th2 cells produce both cytokines, it is probable that Eo recruitment into sites of allergen-induced, Th2-mediated skin reactions is, at least in part, due to IL-4-stimulated induction of eotaxin in dermal fibroblasts.

Keywords:
Eotaxin, Eosinophil, Chemokine, IL-4, Fibroblast
1.
Gaga M, Frew AJ, Varney VA, Kay AB: Eosinophil activation and T lymphocyte infiltration in allergen-induced late phase skin reactions and classical delayed-type hypersensitivity. J Immunol 1991;147:816–822.
2.
Leiferman KM: A current perspective on the role of eosinophils in dermatologic diseases. J Am Acad Dermatol 1991;24:1101–1112.
3.
Robinson DS, Hamid Q, Ying S, Tsicopoulos A, Barkans J, Bentley AM, Corrigan C, Durham SR, Kay AB: Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med 1992;326:298–304.
4.
Vowels BR, Rook AH, Cassin M, Zweiman B: Expression of interleukin-4 and interleukin-5 mRNA in developing cutaneous late-phase reactions. J Allergy Clin Immunol 1995;96:92–96.
5.
Heath H, Qin S, Rao P, Wu L, LaRosa G, Kassam N, Ponath PD, Mackay CR: Chemokine receptor usage by human eosinophils. J Clin Invest 1997;99:178–184.
6.
Mochizuki M, Bartels J, Mallet AI, Christophers E, Schröder JM: IL-4 induces eotaxin: A possible mechanism of selective eosinophil recruitment in helminth infection and atopy. J Immunol 1998;160:60–68.
7.
Sticherling M, Kupper M, Koltrowiz F, Bronscheuer E, Kulke R, Klinger M, Kameyoshi Y, Christophers E, Schröder M: Detection of the chemokine RANTES in cytokine-stimulated human dermal fibroblasts. J Invest Dermatol 1995;105:585–591.
8.
Bartels J, Sculter C, Richter E, Noso N, Kulke R, Christophers E, Schröder M: Human dermal fibroblasts express eotaxin: Molecular cloning, mRNA expression, and identification of eotaxin sequence variants. Biochem Biophys Commun 1996;225:1045–1051.
9.
Petering H, Hochstetter R, Kimming D, Smolarski R, Kapp A, Elsner J: Detection of MCP-4 in dermal fibroblasts and its activation of the respiratory burst in human eosinophils. J Immunol 1998;160:555–558.
10.
Noso N, Sticherling M, Bartels J, Mallet AI, Christophers E, Schröder M: Identification of an N-terminally truncated form of the chemokine RANTES and granulocyte-macrophage colony-stimulating factor as major eosinophil attractants released by cytokine-stimulated dermal fibroblasts. J Immunol 1996;156:1946–1953.
11.
Noso N, Bartels J, Mallet AI, Mochizuki M, Christophers E, Schröder JM: Delayed production of biologically active O-glycosylated forms of human eotaxin by tumor-necrosis-factor-α-stimulated dermal fibroblasts. Eur J Biochem 1998;253:114–122.
12.
MacLean JA, Ownbey R, Luster AD: T cell-dependent regulation of eotaxin in allergen-induced pulmonary eosinophilia. J Exp Med 1996;184:1461–1469.
13.
Ying S, Taborda-Barata L, Meng Q, Humbert M, Kay AB: The kinetics of allergen-induced transcription of messenger RNA for monocyte chemotactic protein-3 and RANTES in the skin of human atopic subjects: Relationship to eosinophil, T cell, and macrophage recruitment. J Exp Med 1995;181:2153–2159.
14.
Marfaing-Koka A, Devergne O, Gorgone G, Portier A, Schall TJ, Galanaud P, Emilie D: Regulation of the production of the RANTES chemokine by endothelial cells. J Immunol 1995;154:1870–1878.
15.
Griffiths-Johnson DA, Collins PD, Rossi AG, Jose PJ, Williams TJ: The chemokine eotaxin activates guinea-pig eosinophils in vitro and causes their accumulation into the lung in vivo. Biochem Biophys Commun 1993;197:1167–1172.
16.
Ponath PD, Qin S, Ringer DJ, Clark-Lewis I, Wang J, Kassam N, Smith H, Shi X, Gonzalo JA, Newman W, Gutierrez-Ramos JC, Mackay CR: Cloning of the human eosinophil chemoattractant, eotaxin. J Clin Invest 1996;97:604–612.
17.
Tepper RI, Pattengale PK, Leder P: Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell 1989;57:503–512.
18.
Rothenberg ME, Luster AD, Leder P: Murine eotaxin: An eosinophil chemoattractant inducible in endothelial cells and in interleukin 4-induced tumor suppression. Proc Natl Acad Sci USA 1995;92:8960–8964.
19.
Sanz MJ, Ponath PD, Mackay CR, Newman W, Miyasaka M, Tamatani T, Flanagan BF, Lobb RR, Williams TJ, Nourshargh S, Jose PJ: Human eotaxin induces α4 and β2 integrin-dependent eosinophil accumulation in rat skin in vivo: Delayed generation of eotaxin in response to IL-4. J Immunol 1998;160:3569–3576.
20.
Steffen M, Abboud M, Potter GK, Yung XP, Moore MAS: Presence of tumor necrosis factor on a related factor in human basophil/mast cells. Immunology 1989;66:445–450.
21.
Barks JL, McQuillan JJ, Iademarco MF: TNF-α and IL-4 synergically increase vascular cell adhesion molecule-1 expression in cultured vascular smooth muscle cells. J Immunol 1997;159:4532–4538.
1999
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.